Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients-Reference-Cited by-同舟云学术

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Published:2016-05-23 Issue:5 Volume:11 Page:e0155959
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Polivkova Vaclava,Rohon Peter,Klamova Hana,Cerna Olga,Divoka Martina,Curik Nikola,Zach Jan,Novak Martin,Marinov Iuri,Soverini Simona,Faber Edgar,Machova Polakova Katerina

Funder

Grant Agency of Ministry of Health of Czech Republic

Internal Grant Agency of Medical Faculty University Palacky,Czech Republic

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference27 articles.

1. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia;M Talpaz;Blood,1983

2. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia;M Talpaz;Leukemia,2013

3. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients;M Talpaz;Ann Intern Med,1991

4. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy;MS Lee;Blood,1992

5. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy;P Rohon;Eur J Haematol,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of chronic myeloid leukemia in 2023 – common ground and common sense;Blood Cancer Journal;2023-04-24

2. Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia;International Journal of Molecular Sciences;2023-01-20

3. B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics;International Journal of Molecular Sciences;2022-10-05

4. Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34+/CD38− Leukemia Stem Cells;Cancers;2022-07-27

5. The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia;British Journal of Haematology;2022-01-06